Table 3.
Clinical outcomes.
| Study | Outcome measures | Pre-op. | 3 days | 1 month | 3 months | 6 months | 12 months | 16 months | 24 months | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Constant score | P value | ||||||||||
| Castricini et al., 2011 [80] | Control group | 42.9 (22–55) | 88.4 (54–100) | <0.001 | |||||||
| PRP group | 42 (30–53) | 88.4 (72–99) | <0.001 | ||||||||
| P value | 0.44 | ||||||||||
|
| |||||||||||
| Randelli et al., 2011 [82] | Constant score | ||||||||||
| Control group | 42.2 ± 15.2 | 57.8 ± 11 | 72.3 ± 12.6 | 75.7 ± 9.5 | 78.7 ± 10 | ||||||
| PRP group | 44 ± 16.5 | 65 ± 9 | 73.1 ± 8.7 | 78.3 ± 6.4 | 82.4 ± 6.3 | ||||||
| P value | 0.6 | 0.02 | 0.7 | 0.3 | 0.1 | ||||||
| UCLA | |||||||||||
| Control group | 14.5 ± 5.6 | 24.2 ± 4.9 | 29.2 ± 4.9 | 31 ± 4.1 | 31.3 ± 4.1 | ||||||
| PRP group | 15.3 ± 5.9 | 26.9 ± 3 | 30.6 ± 4.1 | 31.2 ± 5.2 | 33.3 ± 2.2 | ||||||
| P value | 0.6 | 0.03 | 0.3 | 0.7 | 0.06 | ||||||
| SER (Kg) | |||||||||||
| Control group | 2.3 ± 2 | 2.1 ± 1.3 | 3.3 ± 1.3 | 3.7 ± 1.5 | 4 ± 1.9 | ||||||
| PRP group | 1.9 ± 1.7 | 3 ± 1.6 | 3.9 ± 2.1 | 4.2 ± 2.8 | 4.3 ± 2.3 | ||||||
| P value | 0.4 | 0.04 | 0.2 | 0.5 | 0.5 | ||||||
| SST | |||||||||||
| Control group | 4.7 ± 2.8 | 7.1 ± 2.7 | 10.5 ± 2.3 | 10.6 ± 1.5 | 10.9 ± 1.4 | ||||||
| PRP group | 4.8 ± 3.1 | 8.9 ± 2.2 | 10.6 ± 1.4 | 11.1 ± 0.9 | 11.3 ± 0.9 | ||||||
| P value | 0.9 | 0.02 | 0.9 | 0.3 | 0.3 | ||||||
| VAS | |||||||||||
| Control group | 6.4 ± 2 | 6.3 ± 2.8 | 2.4 ± 2.6 | ||||||||
| PRP group | 4.8 ± 2 | 4 ± 3.2 | 1.1 ± 2.2 | ||||||||
| P value | 0.003 | 0.007 | 0.01 | ||||||||
|
| |||||||||||
| Jo et al. [81], 2011 | Constant Score | ||||||||||
| Control group | 50.78 ± 16.04 | 46.10 ± 17.75 | 64.56 ± 15.98 | 81.36 ± 11.97 | 82.00 ± 13.02 | ||||||
| PRP group | 46.47 ± 16.50 | 33.47 ± 14.39 | 63.36 ± 11.73 | 77.65 ± 13.02 | 79.12 ± 13.42 | ||||||
| P value | 0.397 | 0.036 | 0.910 | 0.493 | 0.476 | ||||||
| UCLA | |||||||||||
| Control group | 16.78 ± 4.73 | 22.00 ± 4.01 | 25.94 ± 4.84 | 29.77 ± 4.36 | 30.83 ± 4.96 | ||||||
| PRP group | 15.89 ± 4.98 | 18.00 ± 7.47 | 26.27 ± 4.43 | 30.12 ± 6.04 | 31.78 ± 6.15 | ||||||
| P value | 0.558 | 0.061 | 0.827 | 0.708 | 0.579 | ||||||
| ASES | |||||||||||
| Control group | 49.60 ± 17.74 | 60.58 ± 16.33 | 71.75 ± 18.21 | 89.19 ± 10.73 | 89.92 ± 17.03 | ||||||
| PRP group | 43.95 ± 20.44 | 46.22 ± 20.06 | 72.63 ± 13.63 | 86.26 ± 19.95 | 87.61 ± 24.83 | ||||||
| P value | 0.343 | 0.031 | 0.530 | 0.712 | 0.744 | ||||||
| DASH | |||||||||||
| Control group | 45.69 ± 25.51 | 38.83 ± 20.14 | 23.80 ± 16.74 | 9.20 ± 9.87 | 8.48 ± 14.05 | ||||||
| PRP group | 52.85 ± 25.29 | 49.61 ± 23.12 | 24.85 ± 16.52 | 12.84 ± 18.89 | 13.19 ± 25.45 | ||||||
| P value | 0.369 | 0.166 | 0.703 | 0.588 | 0.473 | ||||||
| SST | |||||||||||
| Control group | 5.17 ± 2.99 | 5.40 ± 3.57 | 9.06 ± 5.45 | 10.64 ± 1.71 | 10.57 ± 1.73 | ||||||
| PRP group | 4.63 ± 3.29 | 4.40 ± 2.50 | 8.36 ± 2.25 | 9.59 ± 2.85 | 9.83 ± 3.31 | ||||||
| P value | 0.579 | 0.369 | 0.982 | 0.206 | 0.355 | ||||||
| SPADI | |||||||||||
| Control group | 46.25 ± 24.05 | 39.50 ± 23.02 | 25.71 ± 15.52 | 9.83 ± 10.59 | 10.08 ± 16.32 | ||||||
| PRP group | 54.47 ± 28.72 | 56.33 ± 23.97 | 28.69 ± 14.29 | 11.72 ± 18.22 | 12.03 ± 24.96 | ||||||
| P value | 0.318 | 0.045 | 0.745 | 0.869 | 0.673 | ||||||
VAS: Visual Analog Score for Pain; PRP: platelet rich plasma; SER: strength in external rotation; UCLA: University of California; SST: Simple Shoulder Test; ASES: American Shoulder and Elbow Society; DASH: Disabilities of the Arm, Shoulder and Hand; SPADI: Shoulder Pain and Disability Index.